Cardinal Health, Inc. (NYSE:CAH) is included among the 16 Best Dividend Stocks with Rising Payouts.
On February 10, Wells Fargo raised its price recommendation on Cardinal Health, Inc. (NYSE:CAH) to $256 from $237. The firm reiterated its Overweight rating on the stock. The decision followed a strong Q2 performance, which led the firm to lift its earnings estimates. Wells Fargo pointed to broad strength across the business, especially in the Pharmaceutical and Specialty segments. It also noted that the company’s strong momentum in the first half of fiscal 2026 could carry into the second half.
Cardinal Health had already delivered encouraging news on February 5, when it raised its profit outlook for fiscal 2026 after reporting results that came in ahead of expectations. Strong demand for specialty medicines played a major role in the outperformance and helped push the shares up more than 9% in early trading.
During the earnings call, CEO Jason Hollar said that while GLP-1 drugs are contributing to revenue, they are not expected to have a meaningful impact on profits in the near term. He explained that oral GLP-1 treatments are still being adopted gradually and are unlikely to significantly influence results this fiscal year, although they represent a longer-term opportunity.
Cardinal Health now expects adjusted earnings between $10.15 and $10.35 per share, an improvement from its earlier forecast of at least $10. The company also reported quarterly revenue of $65.63 billion, which came in above expectations, while adjusted earnings of $2.63 per share also exceeded estimates.
Cardinal Health, Inc. (NYSE:CAH) is a global healthcare services and products company that works with hospitals, pharmacies, and healthcare providers. It supplies pharmaceuticals and medical products while also offering services that help improve efficiency and support patient care across the healthcare system.
While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Best Roth IRA Stocks to Buy Now and 13 Cheapest Dividend Aristocrats to Invest in
Disclosure: None.
